MARYICEF

This brand name is authorized in Nigeria.

Active ingredients

The drug MARYICEF contains one active pharmaceutical ingredient (API):

1	Cefixime UNII 97I1C92E55 - CEFIXIME
	Cefixime is an oral third generation cephalosporin which has marked in vitro bactericidal activity against a wide variety of Gram-positive and Gram-negative organisms.
	Read more about Cefixime

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-1230	Dispersible tablet	Maryicef-200 Tablet TAB_ORALLY_DIS 200 mg 1 x 10's (in Alu-Alu blister)	Uncoated dispersible tablet. White to white off, round shape uncoated dispersible tablet with one side break-line and plain on the other side of the tablet	30/04/2025
B4-2130	Tablet	Maryicef 400 Tablets TAB 400 mg 1 x 10's (in Alu-Alu blister)	Film-coated Tablet. White to white off, oval shaped, biconvex, film-coated tablet, plain on both sides	30/04/2025

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01DD08	Cefixime	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DD Third-generation cephalosporins
Discover more medicines within J01DD08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-1230, B4-2130